The National Primary Health Care Development Agency (NPHCDA) has disclosed that a total of 8,439 mild Adverse Events Following Immunization (AEFI) cases have been reported since the commencement of the vaccination program in Nigeria.
The Executive Director of NPHCDA, Dr. Faisal Shuaib, disclosed this in Abuja on Friday at a media briefing organised by the agency and the World Health Organisation (WHO) to give an update on the status of COVID-19 vaccination in the country.
According to the briefing, Faisal noted that cases of death or blood clot after administration of vaccine haven’t been recorded.
“There has been no death from administration of the vaccine. We have also not diagnosed any case of blood clots related to the administration of the vaccines.
“Nevertheless, we are working with NAFDAC, NCDC and other relevant agencies to set up a more active surveillance system built on our experience with polio surveillance.”
Faisal also stated that since the vaccination program was officially rolled out, a total of 8,439 mild Adverse events following immunization (AEFI) have been reported in Nigeria. These range from pain, swelling at the site of the inoculation, to body pains and nausea.
Similarly, 52 cases of moderate to severe incidents of AEFI have been reported. These presented as fever, vomiting, diarrhea headaches, dizziness and allergic reactions.
Five states reported the highest cases of the AEFI namely: Kaduna (970) Cross River (859), Yobe (541), Kebbi (511), and Lagos (448).
However, NPHCDA warned the general public that the Federal Government of Nigeria through the PSC has only one channel of distributing the COVID-19 vaccines to all Nigerians.
It also noted that the ongoing vaccination is only available in designated health centers as structured by the NPHCDA, which is the primary agency under the Federal Ministry of Health (FMoH), charged with the responsibility of all vaccine related matters.
Faisal also assured Nigerians of safety as it stated that NPHCDA is working with NAFDAC, NCDC and other related agencies to ensure that no unauthorized or counterfeit process is introduced from foreign countries.
In addition, the executive director of NPHCDA stated that over one million people representing 53.2% of the eligible persons targeted have been administered the first dose of AstraZeneca vaccine.
“As of today, April 16th, 1,071,346 representing 53.2% of the eligible persons targeted with the Astrazeneca vaccine have been administered their first dose in this vaccination phase.” He stated.